N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor

US8343959B2 · kind B2 · utility

Assignees

• Abbott GmbH & Co. KG · DE
• Abbott Laboratories · US

Inventors

• Andreas Haupt · Ludwigshafen, DE
• Frauke Pohlki · Wiesbaden, DE
• Karla Drescher · Ludwigshafen, DE
• Karsten Wicke · Ludwigshafen, DE
• Liliane Unger · Ludwigshafen, DE
• Ana-Lucia Relo · Ludwigshafen, DE
• Anton Bespalov · Ludwigshafen, DE
• Barbara Vogg · Ludwigshafen, DE
• Gisela Backfisch · Dossenheim, DE
• Juergen Delzer · Ludwigshafen, DE
• Min Zhang · 安丰镇, CN
• Yanbin Lao · Libertyville, US

Key dates

• Filing date: Oct 28, 2011
• Grant date: Jan 1, 2013
• Expiry date: Oct 28, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D317/46
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HT6 receptor.